UNSPSC 51182218: Carboprost trometamol

This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4526F86FJ. European Medicines Agency schedules Carboprost trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01053MIG. Carboprost trometamol generally arises in the molecular formula C21H36O5.C4H11NO3. The term 'carboprost trometamol' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule carboprost trometamol under HS 29375000 and SITC 54156.

SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.

UNSPSC 51182218 Carboprost trometamol, a Commodity code, addresses pharmaceutical products that state and local government health systems, correctional facilities, and public agencies procure through cooperative purchasing vehicles and direct manufacturer contracts. State and local buyers source this and related pharmaceutical commodities primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and consolidate pricing negotiations with authorized pharmaceutical wholesalers. The scope of work under this code encompasses manufacturer pricing, product compliance documentation (including cGMP certification and Drug Supply Chain Security Act compliance), electronic data interchange capability, and management of inventory distribution through contracted wholesaler channels. Issuing bodies include state departments of administration, multistate purchasing cooperatives, county health departments, and municipal healthcare facilities that rely on cooperative agreements to meet pharmaceutical procurement requirements at scale.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions. The solicitation requires manufacturers to supply comprehensive product information keyed to specific National Drug Codes, maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co.), carry insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability, and accept a 3 percent administrative fee on all contract purchases with performance penalties of $200 to $1,500 per violation. Awarded contracts become effective July 1, 2026, with a two-year initial term and optional extensions; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent combined on administrative compliance, EDI capability, and administrative fee acceptance.